---
title: Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical
  responses in secondary CNS lymphoma
date: '2024-03-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38484137/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240315180553&v=2.18.0.post9+e462414
source: Blood
description: Although CD20xCD3 bispecific antibodies are effective against systemic
  B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the
  CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates
  immune-cell infiltration of CNS tumors, and induces responses in CNS ...
disable_comments: true
---
Although CD20xCD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces responses in CNS ...